Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) Receives Average Recommendation of “Strong Buy” from Analysts

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price target of $2.00 for the company, according to Zacks. Zacks has also given Invivo Therapeutics an industry rank of 105 out of 255 based on the ratings given to its competitors.

NASDAQ:NVIV remained flat at $$0.48 on Tuesday. 49,201 shares of the company traded hands, compared to its average volume of 14,475. The stock has a market cap of $4.47 million, a PE ratio of -0.21 and a beta of 1.54. The company has a quick ratio of 5.72, a current ratio of 5.72 and a debt-to-equity ratio of 0.11. The company’s 50 day moving average price is $0.56 and its 200 day moving average price is $0.86. Invivo Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $2.75.

Invivo Therapeutics (NASDAQ:NVIV) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.34) EPS for the quarter. As a group, equities analysts expect that Invivo Therapeutics will post -1.25 earnings per share for the current fiscal year.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.

See Also: What is quantitative easing?

Get a free copy of the Zacks research report on Invivo Therapeutics (NVIV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.